Skip to Content

Compugen Ltd CGEN

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Compugen Ltd is a therapeutic discovery company. It is involved in the business of using its predictive discovery infrastructure to identify novel drug targets and develop biologics. The firm's therapeutic pipeline mainly consists of early-stage immuno-oncology programs aimed at harnessing the immune system to fight cancer. It focuses on immune checkpoint target candidates which are predicted to serve drug targets for cancer immunotherapies addressing various cancer types and also autoimmune diseases.

26 Harokmim Street, Building D, Azrieli Center,
Holon, 5885849, Israel
T +972 37658585
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 68